Henry D H
Department of Medicine, University of Pennsylvania School of Medicine, Graduate Hospital Division of Hematology/Oncology, Philadelphia.
Hematol Oncol Clin North Am. 1994 Oct;8(5):961-73.
Anemia is common in cancer patients and may require treatment for symptomatic palliation. Transfusion has been the mainstay of therapy, but is not without risk. Because erythropoietin levels in cancer-related anemia are inadequate for the degree of anemia, recombinant human erythropoietin has been studied to treat the anemia. Results from these studies are encouraging.
贫血在癌症患者中很常见，可能需要进行治疗以缓解症状。输血一直是主要的治疗方法，但并非没有风险。由于癌症相关性贫血患者的促红细胞生成素水平不足以应对贫血程度，因此人们对重组人促红细胞生成素治疗贫血进行了研究。这些研究结果令人鼓舞。
